Ebelt Nancy D, Zamloot Vic, Manuel Edwin R
Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Oncotarget. 2020 Sep 22;11(38):3486-3488. doi: 10.18632/oncotarget.27745.
Pancreatic cancer is considered one of the most lethal cancers in the US. It contributes to an estimated 47,000 deaths annually and is predicted to surpass prostate, breast and colorectal cancers as the leading cause of cancer-related death. Although major advancements in cancer treatment have improved outcomes for many cancer types, survival rate for pancreatic cancer has not improved in nearly four decades despite tremendous effort. One attribute of pancreatic cancer that is considered a major barrier to effective treatment is the formation of fibrotic tissue around tumor cells known as desmoplasia. A number of promising approaches have been developed to deplete fibrotic components in pancreatic tumors to enhance drug delivery, some of which have been tested in clinical trials of advanced, unresectable pancreatic cancer. Here, we discuss previous efforts, shortcomings and new considerations for developing more effective agents to eliminate desmoplasia.
胰腺癌被认为是美国最致命的癌症之一。它每年导致约47000人死亡，预计将超过前列腺癌、乳腺癌和结直肠癌，成为癌症相关死亡的主要原因。尽管癌症治疗取得了重大进展，改善了许多癌症类型的治疗效果，但尽管付出了巨大努力，胰腺癌的生存率近四十年来并未提高。胰腺癌的一个被认为是有效治疗主要障碍的特征是肿瘤细胞周围形成纤维化组织，即促结缔组织增生。已经开发了一些有前景的方法来减少胰腺肿瘤中的纤维化成分以增强药物递送，其中一些已在晚期不可切除胰腺癌的临床试验中进行了测试。在此，我们讨论以前的努力、缺点以及开发更有效药物以消除促结缔组织增生的新考虑因素。
